US Patent

US11904046 — Hydrocortisone oral liquid formulations

Method of Use · Assigned to Eton Pharmaceuticals Inc · Expires 2043-02-23 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects oral liquid formulations of hydrocortisone for the treatment of certain diseases, including endocrine disorders and dermatologic diseases.

USPTO Abstract

Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

Drugs covered by this patent

Cortef (hydrocortisone) · Generic (originally Merck/Upjohn)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4216`	—	Cortef

Patent Metadata

Patent number: US11904046
Jurisdiction: US
Classification: Method of Use
Expires: 2043-02-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Eton Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.